<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292340</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-SARS-CoV-2</org_study_id>
    <nct_id>NCT04292340</nct_id>
  </id_info>
  <brief_title>Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</brief_title>
  <official_title>The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is
      an obsevational study, the investigators collected the clinical information and clinical
      outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The
      study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent
      plasma in the treatment of COVID-19 pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1</measure>
    <time_frame>1 day after receiving plasma transmission</time_frame>
    <description>The SARS-CoV-2 nuclei acid was quantified using RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</measure>
    <time_frame>3 days after receiving plasma transmission</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</measure>
    <time_frame>7 days after receiving plasma transmission</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of participants with different Clinical outcomes</measure>
    <time_frame>From receiving plasma transmission to 4 weeks</time_frame>
    <description>Clinical outcomes include death, critical illness, recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>4 weeks after receiving plasma transmission</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Coronavirus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants received anti-SARS-CoV-2 inactivated convalescent plasma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participants were diagnosed as COVID-19;

          -  Participants received anti-SARS-CoV-2 inactivated convalescent plasma

          -  Written the informed consent.

        Exclusion Criteria:

          -  Participants lacked detailed medical history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Plasma transfusion</keyword>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

